Daily Anesthesiology Research Analysis
Analyzed 104 papers and selected 3 impactful papers.
Summary
Analyzed 104 papers and selected 3 impactful articles.
Selected Articles
1. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
In this multicenter randomized noninferiority trial in ECMO patients, both low-dose UFH and therapeutic LMWH were noninferior to standard-dose UFH for a composite of severe bleeding, severe thromboembolism, or 6-month mortality. Severe bleeding occurred less often with lower-intensity strategies without an excess of thromboembolic events, supporting reconsideration of anticoagulation targets in ECMO.
Impact: This is the first adequately powered randomized trial to compare anticoagulation intensities during ECMO, directly informing a high-stakes standard of care with potential to reduce bleeding-related harm.
Clinical Implications: Lower-intensity anticoagulation (low-dose UFH or therapeutic LMWH) can be considered as alternatives to standard-dose UFH in ECMO, potentially reducing severe bleeding without increasing thromboembolism; centers should revisit anticoagulation protocols.
Key Findings
- Composite primary outcome occurred in 87/107 (81%) standard-dose UFH, 78/108 (72%) low-dose UFH (risk difference -9.1 percentage points; 95% CI -20.3 to 2.1), and 79/105 (75%) LMWH (-6.1; 95% CI -17.2 to 5.0), meeting noninferiority.
- Severe bleeding was numerically lower with low-dose UFH (58%) and LMWH (59%) versus standard-dose UFH (65%), without excess severe thromboembolic events (10% and 9% vs 11%).
- Six-month mortality was 50% (standard-dose UFH), 42% (low-dose UFH), and 44% (LMWH).
Methodological Strengths
- Multicenter randomized noninferiority design with adequate sample size and intention-to-treat analysis
- Direct comparison of three clinically relevant anticoagulation strategies with prespecified noninferiority margin
Limitations
- Open-label design with potential for performance bias
- Composite endpoint may obscure differences in individual components; secondary outcomes did not reach statistical significance
Future Directions: Head-to-head blinded trials or pragmatic registries could refine patient selection, evaluate bleeding phenotypes, and assess cost-effectiveness and outpatient transitions between UFH and LMWH.
BACKGROUND: In patients receiving extracorporeal membrane oxygenation (ECMO), standard practice is full-dose intravenous unfractionated heparin (UFH) targeting an activated partial thromboplastin time of 2·0-2·5 times baseline to reduce thrombotic risk. This approach can increase bleeding without further reducing thrombosis compared with low-dose UFH. Robust evidence to guide anticoagulation targets is absent because anticoagulation targets in ECMO have never been assessed in a sufficiently pow
2. Single-Encounter Augmented Reality-Guided Localization for Resection of Suspected Early-Stage Lung Cancer: A Randomized Clinical Trial.
In a 5-center randomized noninferiority trial (mITT n=270), AR-guided single-encounter localization under general anesthesia achieved noninferior successful sublobar resection (98.5% vs 99.3%). AR significantly reduced radiation exposure, preoperative pain, puncture time, and localization-to-incision delays; pneumothorax occurred in 29.4% of CT-guided cases.
Impact: Demonstrates a scalable, patient-centered workflow that consolidates localization and resection into one anesthetic encounter while improving safety metrics.
Clinical Implications: AR-guided single-encounter localization can replace multi-encounter CT-guided workflows for eligible nodules, reducing radiation, pain, and delays while maintaining oncologic adequacy.
Key Findings
- Successful sublobar resection: 98.5% (132/134) AR vs 99.3% (135/136) CT; risk difference -0.8 percentage points (95% CI -2.7 to 3.9), meeting noninferiority.
- Radiation exposure markedly lower with AR (median 456.50 mGy·cm) vs CT (1260.11 mGy·cm); P < .001.
- AR reduced preoperative pain (NRS median 0 vs 5), puncture time (0.63 vs 6.50 min), and localization-to-incision interval (2.00 vs 33.50 min); all P < .001.
- Pneumothorax occurred in 29.4% of CT-guided cases.
Methodological Strengths
- Multicenter randomized noninferiority design with mITT analysis and trial registration
- Comprehensive outcomes including technical success, radiation dose, patient-reported pain, and efficiency metrics
Limitations
- Conducted in five centers within one country; generalizability to other health systems may vary
- Learning curve and operator expertise for AR guidance may influence performance
Future Directions: Broader implementation studies assessing cost-effectiveness, learning curves, and outcomes across diverse centers; evaluation in more complex nodules and with different AR platforms.
IMPORTANCE: Preoperative localization is often required to achieve successful sublobar resection with adequate margins for computed tomography (CT)-detected pulmonary nodules suspicious for early-stage lung cancer. Conventional CT-guided localization involves a multiple-encounter workflow that may cause pain, radiation exposure, and complications. OBJECTIVE: To determine whether a single-encounter augmented reality (AR)-guided percutaneous localization strategy is noninferior to standard multiple-encounter CT-guided localization for achieving successful sublobar resection. DESIGN, SETTING, AND PARTICIP
3. Pulse pressure variation-guided versus low central venous pressure-guided fluid management during elective open hepatectomy: a randomized non-inferiority trial.
In 64 adults undergoing elective open hepatectomy, PPV-guided fluid management was noninferior to LCVP-guided management for intraoperative blood loss (683±276 ml vs 726±223 ml; mean difference -43 ml, 95% CI -169 to 83; below the 98-ml noninferiority margin). Other perioperative parameters, including fluids, urine output, lactate, and 24-hour creatinine, were similar.
Impact: Supports replacing a static preload target (CVP) with a dynamic fluid responsiveness index (PPV) in liver resection, aligning with goal-directed hemodynamics.
Clinical Implications: PPV-guided fluid management is a feasible alternative to LCVP targeting during open hepatectomy without compromising blood loss or perfusion markers; it may simplify monitoring and standardize practice.
Key Findings
- Intraoperative blood loss: 683±276 ml (PPV) vs 726±223 ml (LCVP); mean difference -43 ml (95% CI -169 to 83), meeting noninferiority (margin 98 ml).
- Total crystalloids/colloids, urine output, surgical field grading, and perioperative lactate were similar between groups.
- Postoperative serum creatinine at 24 hours showed no significant difference.
Methodological Strengths
- Randomized noninferiority design with predefined hemodynamic algorithms
- Clinically relevant primary outcome (blood loss) and multiple perioperative safety markers
Limitations
- Single-center study with a modest sample size may limit generalizability and power for rare complications
- ASA I–II adults undergoing open resections; findings may not extend to laparoscopic surgery or higher-risk cohorts
Future Directions: Larger multicenter trials comparing PPV thresholds, integration with vasopressor strategies, and evaluation in minimally invasive hepatectomy and cirrhotic populations.
BACKGROUND: Low central venous pressure (LCVP)-guided fluid management is widely used to reduce blood loss during liver resection; however, LCVP is an unreliable marker of preload. Pulse pressure variation (PPV) is a dynamic index of fluid responsiveness. This study evaluated whether a PPV-guided fluid management strategy is non-inferior to conventional LCVP-guided management in reducing intraoperative blood loss during elective open hepatectomy. METHODS: In this single-center, randomized, non-